GUARNERI, VALENTINA

GUARNERI, VALENTINA  

Dipartimento di Scienze Chirurgiche Oncologiche e Gastroenterologiche - DiSCOG  

Mostra records
Risultati 1 - 20 di 262 (tempo di esecuzione: 0.038 secondi).
Titolo Data di pubblicazione Autori Rivista Serie Titolo libro
119P The role of circulating markers in predicting immune-related adverse events (irAEs) and their recurrence in advanced non-small cell lung cancer (aNSCLC) patients (pts) 2021 Dal Maso, A.Ferro, A.Pretelli, G.Frega, S.Menis, J.Pasello, G.Guarneri, V.Conte, P. F. + JOURNAL OF THORACIC ONCOLOGY - -
1398P Real-life progression (PD) pattern of EGFR mutant advanced non-small cell lung cancer (aNSCLC) patients (pts) receiving systemic therapy after first- or second-generation tyrosine kinase inhibitor (1-2 gen TKI) 2020 Dal Maso, A.Ferro, A.Lorenzi, M.Scattolin, D.Del Conte, A.Frega, S.Indraccolo, S.Calabrese, F.Guarneri, V.Conte, P. F.Pasello, G. + ANNALS OF ONCOLOGY - -
149P First-line (1L) osimertinib in EGFR mutant (mut) advanced non-small cell lung cancer (aNSCLC) patients (pts): Progression (PD) pattern and safety in the real-world (RW) 2021 Lorenzi, M.Dal Maso, A.Ferro, A.Scattolin, D.Indraccolo, S.Frega, S.Menis, J.Guarneri, V.Conte, P. F.Pasello, G. + JOURNAL OF THORACIC ONCOLOGY - -
18F-Fluoroestradiol Positron Emission Tomography In Breast Cancer Patients: Systematic Review Of The Literature &; Meta-Analysis 2016 DIECI, MARIA VITTORIAGUARNERI, VALENTINACONTE, PIERFRANCO + CURRENT RADIOPHARMACEUTICALS - -
51P Liver kinase B1 (LKB1) and phosphorylated AMP kinase (AMPK) expression in small cell lung cancer (SCLC): Association with prognosis and tumour immune microenvironment (TIME) features 2021 Dal Maso, A.Zulato, E.Fassan, M.Pasello, G.Guarneri, V.Calabrese, F.Rea, F.Indraccolo, S.Conte, P. F. + JOURNAL OF THORACIC ONCOLOGY - -
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study 2018 Conte, PGuarneri, V + ANNALS OF ONCOLOGY - -
9 Weeks vs 1 Year Adjuvant Trastuzumab in Combination with Chemotherapy: Preliminary Cardiac Safety Data of the Phase III Multicentric Italian Study Short-HER. 2010 Guarneri VCONTE, PIERFRANCO + CANCER RESEARCH - -
A prognostic model based on nodal status and Ki 67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy 2009 GUARNERI, VALENTINACONTE, PIERFRANCO + CANCER RESEARCH - -
A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy. 2009 GUARNERI, VALENTINACONTE, PIERFRANCO + ANNALS OF ONCOLOGY - -
Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR1, HER22, node-positive, high-risk, early breast cancer (monarchE) 2020 Guarneri V. + JOURNAL OF CLINICAL ONCOLOGY - -
Achievements and unmet needs in the management of advanced ovarian cancer 2010 GUARNERI, VALENTINACONTE, PIERFRANCO + GYNECOLOGIC ONCOLOGY - -
Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy 2004 GUARNERI, VALENTINACONTE, PIERFRANCO + BRITISH JOURNAL OF CANCER - -
Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study 2021 Guarneri V. + ANNALS OF ONCOLOGY - -
Agreement between MRI and pathologic breast tumor size after neoadjuvant chemotherapy, and comparison with alternative tests: Individual patient data meta-analysis 2015 GUARNERI, VALENTINA + BMC CANCER - -
Analysis of Bevacizumab (Bev) Therapy, Bisphosphonate Use and Osteonecrosis of the Jaw (ONJ) in >1900 Patients Treated in Two Randomized, Controlled Trials 2009 GUARNERI, VALENTINACONTE, PIERFRANCO + CANCER RESEARCH - -
Analysis of Bevacizumab (Bev) Therapy, Bisphosphonate Use and Osteonecrosis of the Jaw (ONJ) in >1900 Patients Treated in Two Randomized, Controlled Trials 2009 Guarneri VCONTE, PIERFRANCO + CANCER RESEARCH - -
Androgen receptor expression and association with distant disease-free survival in triple negative breast cancer: Analysis of 263 patients treated with standard therapy for stage I-III disease 2019 Dieci M. V.TSVETKOVA, VASSILENAGriguolo G.Miglietta F.MANTIERO, MARACumerlato E.Giorgi C. A.Giarratano T.FAGGIONI, GIULIA MARTINAVernaci G.Menichetti A.MIORANZA, ELEONORAFREZZINI, SIMONAOrvieto E.Guarneri V. + FRONTIERS IN ONCOLOGY - -
Anthracycline-based preoperative chemotherapy plus lapatinib and trastuzumab or both in HER2-positive breast cancer: Preliminary cardiac safety report of the CHER LOB trial. 2009 V. GuarneriCONTE, PIERFRANCO + JOURNAL OF CLINICAL ONCOLOGY - -
Anthracyclines in the treatment of patients with early breast cancer 2022 Guarneri, V + ESMO OPEN - -
Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer. 2010 GUARNERI, VALENTINADIECI, MARIA VITTORIACONTE, PIERFRANCO + CANCER TREATMENT REVIEWS - -